Description: Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. In addition, the company provides contract manufacturing services. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Home Page: www.wockhardt.com
Wockhardt Towers
Mumbai,
400051
India
Phone:
91 24 0669 4444
Officers
| Name | Title |
|---|---|
| Dr. Habil Fakhruddin Khorakiwala | Founder & Executive Chairman |
| Dr. Murtaza Habil Khorakiwala | MD & Executive Director |
| Dr. Huzaifa Habil Khorakiwala | Executive Director |
| Mr. Deepak R. Madnani | Chief Financial Officer |
| Dr. Mahesh Vithalbhai Patel | Chief Scientific Officer of New Drug Discovery |
| Ms. Debolina Partap | Senior Vice President of Legal |
| Mr. Neeraj Agarwal | Chief Human Resource Officer |
| Mr. Anil V. Kamath AMRSH (Lon.), BCom (Hons), MBIM (Lon.), MIMA | Senior Vice President of Business Development |
| Mr. Zoher T. Sihorwala | Head of Global Regulatory Affairs |
| Mr. Prakash Gupta | President of Supply Chain |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.6484 |
| Price-to-Sales TTM: | 7.7131 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 2386 |